amicus
therapeutics
receives
european
medicines
agency
prime
designation
batten
disease
gene
therapy
cranbury
globe
newswire
amicus
therapeutics
nasdaq
fold
global
biotechnology
company
focused
discovering
developing
delivering
novel
medicines
rare
diseases
today
announced
european
medicines
agency
ema
granted
priority
medicines
prime
designation
company
investigational
gene
therapy
children
living
variant
late
infantile
neuronal
ceroid
lipofuscinosis
disease
also
known
batten
disease
prime
initiative
provides
enhanced
support
increased
interaction
developers
promising
medicines
goal
optimizing
development
plans
speeding
regulatory
evaluations
goal
ema
prime
help
patients
benefit
early
possible
innovative
new
therapies
demonstrated
potential
significantly
address
unmet
medical
need
prime
designation
based
data
ongoing
phase
clinical
trial
evaluating
single
dose
treatment
children
batten
disease
additional
information
trial
available
pleased
ema
recognized
potential
gene
therapy
based
preliminary
clinical
data
believe
could
potentially
transformative
treatment
option
children
living
batten
disease
debilitating
condition
presents
early
childhood
often
associated
childhood
death
said
john
crowley
chairman
chief
executive
officer
look
forward
continuing
work
closely
ema
accelerate
development
first
potential
treatment
option
children
living
batten
additional
data
ongoing
phase
clinical
study
presented
child
neurology
society
annual
meeting
october
regulatory
interactions
ongoing
company
expects
provide
feedback
path
forward
early
previously
granted
rare
pediatric
disease
orphan
drug
designations
united
states
food
drug
administration
eu
company
holds
prime
orphan
medicinal
product
designations
novel
gene
therapy
phase
development
batten
disease
rare
fatal
inherited
lysosomal
disorder
approved
treatment
primarily
affects
nervous
system
dosed
intrathecal
infusion
deliver
functional
copy
gene
cells
central
nervous
system
therapy
designed
address
underlying
enzyme
deficiency
results
progressive
cell
damage
neurodevelopmental
physical
decline
batten
disease
batten
disease
common
name
broad
class
rare
fatal
inherited
disorders
nervous
system
also
known
neuronal
ceroid
lipofuscinoses
ncls
disorders
defect
specific
gene
triggers
cascade
problems
interferes
cell
ability
recycle
certain
molecules
gene
called
cln
ceroid
lipofuscinosis
neuronal
given
different
number
designation
subtype
known
forms
batten
disease
often
referred
various
types
batten
disease
similar
features
symptoms
vary
severity
age
onset
forms
batten
disease
ncls
usually
begin
childhood
clinical
course
often
involves
progressive
loss
independent
adaptive
skills
mobility
feeding
communication
patients
may
also
experience
vision
loss
personality
changes
behavioral
problems
learning
impairment
seizures
patients
typically
experience
progressive
loss
motor
function
eventually
become
bedridden
die
prematurely
amicus
therapeutics
amicus
therapeutics
nasdaq
fold
global
biotechnology
company
focused
discovering
developing
delivering
novel
medicines
people
living
rare
metabolic
diseases
extraordinary
patient
focus
amicus
therapeutics
committed
advancing
expanding
robust
pipeline
medicines
rare
metabolic
diseases
information
please
visit
company
website
follow
twitter
linkedin
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
relating
preclinical
clinical
development
product
candidates
timing
reporting
results
preclinical
studies
clinical
trials
prospects
timing
potential
regulatory
approval
product
candidates
particular
press
release
relates
interim
data
ongoing
phase
study
investigate
intrathecal
administration
gene
therapy
inclusion
statements
arising
interim
data
ongoing
study
natural
history
preliminary
data
regarded
representation
us
plans
achieved
statements
press
release
may
turn
wrong
affected
inaccurate
assumptions
might
make
known
unknown
risks
uncertainties
example
respect
statements
regarding
goals
progress
timing
outcomes
discussions
regulatory
authorities
particular
potential
goals
progress
timing
results
preclinical
studies
clinical
trials
actual
results
may
differ
materially
set
forth
release
due
risks
uncertainties
inherent
business
including
without
limitation
potential
results
clinical
preclinical
studies
indicate
product
candidates
unsafe
ineffective
potential
may
difficult
enroll
patients
clinical
trials
potential
regulatory
authorities
including
fda
ema
pmda
may
grant
may
delay
approval
product
candidates
potential
preclinical
clinical
studies
could
delayed
identify
serious
side
effects
safety
issues
potential
need
additional
funding
complete
studies
results
earlier
preclinical
studies
clinical
trials
may
predictive
future
results
interim
data
phase
study
discussed
herein
inherently
preliminary
early
study
derived
limited
patient
set
later
trial
results
patient
set
others
may
consistent
preliminary
results
addition
statements
subject
risks
detailed
annual
report
form
year
ended
december
quarterly
report
form
quarter
ended
june
cautioned
place
undue
reliance
statements
speak
date
hereof
statements
qualified
entirety
cautionary
statement
undertake
obligation
revise
update
news
release
reflect
events
circumstances
date
hereof
contacts
investors
amicus
therapeutics
andrew
faughnan
director
investor
relations
afaughnan
media
amicus
therapeutics
diana
moore
head
global
corporate
communications
dmoore
